Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 41-50 of 122 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trialNicholls, S.; Ray, K.; Ballantyne, C.; Beacham, L.; Miller, D.; Ruotolo, G.; Nissen, S.; Riesmeyer, J.
2014Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURNPuri, R.; Nissen, S.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Libby, P.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S.
2016Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: results from the VOYAGER meta-analysisKarlson, B.; Palmer, M.; Nicholls, S.; Lundman, P.; Barter, P.
2016Coronary atheroma progression rates in men and women following high-intensity statin therapy: a pooled analysis of REVERSAL, ASTEROID and SATURNStegman, B.; Shao, M.; Nicholls, S.; Elshazly, M.; Cho, L.; King, P.; Kapadia, S.; Tuzcu, M.; Nissen, S.; Puri, R.
2019Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiographyLin, A.; Nerlekar, N.; Rajagopalan, A.; Yuvaraj, J.; Modi, R.; Mirzaee, S.; Munnur, R.; Seckington, M.; Doery, J.; Seneviratne, S.; Nicholls, S.; Wong, D.
2019The effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trialShishikura, D.; Kataoka, Y.; Honda, S.; Takata, K.; Kim, S.; Andrews, J.; Psaltis, P.; Sweeney, M.; Kulikowski, E.; Johansson, J.; Wong, N.; Nicholls, S.
2015Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: insights from AQUARIUSPuri, R.; Nissen, S.; Menon, V.; Shao, M.; Hsu, A.; Bakris, G.; Kastelein, J.; Williams, B.; Armbrecht, J.; Brunel, P.; Kataoka, Y.; Nicholls, S.
2013Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialLincoff, M.; Tardif, J.; Neal, B.; Nicholls, S.; Ryden, L.; Schwartz, G.; Malmberg, K.; Buse, J.; Henry, R.; Wedel, H.; Weichert, A.; Cannata, R.; Grobbee, D.
2013C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapyPuri, R.; Nissen, S.; Libby, P.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S.
2018The relationship between segmental wall shear stress and lipid core plaque derived from near-infrared spectroscopyShishikura, D.; Sidharta, S.; Honda, S.; Takata, K.; Kim, S.; Andrews, J.; Montarello, N.; Delacroix, S.; Baillie, T.; Worthley, M.; Psaltis, P.; Nicholls, S.